Normally I might be inclined to agree with you; however, because this is a drug delivery system and not a compound with a toxicity profile that is questionable, I won't.
Nuvilex's treatment is quite the opposite actually and has no side effects associated with the treatment.
As an added bonus, it dramatically improves one year survival rate and median survival time over the current standard.
As an additional bonus, the company's COO was the project manager on what might be the most successful cancer drug ever developed... Taxol. He knows all of the ins and outs of dealing with the FDA.
As a bonus to the bonus, the world's leading expert in pancreatic cancer Dr. Daniel Von Hoff, who developed the single agent standard for pancreatic cancer, Gemzar - And the current standard Abraxane plus gemcitabine, Has chosen to work with Nuvilex's pancreatic cancer treatment in clinical trials. Dr. Von Hoff sat on the FDAs advisory board for many years and has conducted over 200 clinical trials and gotten FDA approval on many, many drugs, so I know he knows all the ins and outs to gaining FDA approval.
As a cherry on top bonus, Nuvilex just announced that Dr. Matthias Lohr has agreed to work with Nuvilex's treatment as well. He is quite possibly the Dr. Von Hoff of Europe and led the first two very successful trials that were awarded Orphan Drug status and approved for Phase III before Austrianova ran out of money.
So, with all that said, I will not only choose to believe FDA approval is a lock, I will go as far as saying I bet the treatment gets FDA approval for more than one use.
